Showing 1631-1640 of 9904 results for "".
Experts React to Latest Benzene Analysis
https://practicaldermatology.com/series/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improvCurrent and Future Treatments
https://practicaldermatology.com/series/updates-vitiligo/current-and-future-treatments/26622/Dr. Karan Lal, a double board-certified adult and pediatric dermatologist and fellowship-trained cosmetic dermatologist with Affiliated Dermatology in Scottsdale, Arizona, talks with Practical Dermatology about the various options available today for repigmentation and treating flare-ups in vitiligoRecap of Maui Derm Hawaii Meeting
https://practicaldermatology.com/series/dermwire-tv/recap-of-maui-derm-hawaii-meeting/32717/In this week's DermwireTV, key stakeholders in dermatology gather in Hawaii to discuss the latest developments and advances; a new review examines whether IgE-targeting therapies could represent a new treatment avenue for psoriasis and atherosclerosis; and the founder of SEEN hair care joEmrosi Launched in the US for Rosacea
https://practicaldermatology.com/series/dermwire-tv/emrosi-launched-in-the-us-for-rosacea/33943/In this week's DermwireTV, a new treatment for rosacea is launched in the US; long-term data is presented for tapinarof 1% cream for atopic dermatitis; and in our C-Suite Chats segment, we speak with the CEO and Co-Founder of Mama Sol.New FDA Approval for AD
https://practicaldermatology.com/series/c-suite-chats/new-fda-approval-for-ad/29911/Phil Brown, MD, JD, Dermatologic Scientific Lead at Organon, talks about the importance of a new FDA-approved topical solution for treating atopic dermatitis.Can Vitamin B3 Reduce Recurrence of NMSC?
https://practicaldermatology.com/topics/practice-management/can-vitamin-b3-reduce-recurrence-of-nmsc/21165/A common OTC vitamin supplement shows early promise in preventing secondary NMSCs. Is it time to recommend it?DermWireTV: Qwo Approved, Assessing Resident Anxiety
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-qwo-approved-assessing-resident-anxiety/19830/FDA has approved Qwo (collagenase clostridium histolyticum-aaes) from Endo, the first injectable treatment approved for moderate to severe cellulite in the buttocks of adult women. A recent survey offers perspective on anxiety among third-year dermatology residents in light of the COVID crisis. AlleJournal Club: Comparing Recommendations from Different AD Guidelines
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-comparing-recommendations-from-different-ad-guidelines/24466/Peter Lio, MD, talks with Robert Sidbury, MD, MPH, a pediatric dermatologist at Seattle Children's Hospital, about some of the differences in recommendations from the Annals of Allergy, Asthma, and Immunology Joint Task Force AD guidelines, and the Journal of the American Academy of Dermatology (JAAFirst Cell-Based Gene Therapy for RDEB
https://practicaldermatology.com/series/dermwire-tv/first-cell-based-gene-therapy-for-rdeb/35742/In this week's DermwireTV, the FDA approves the first cell-based gene therapy for recessive dystophic epidermolysis bullosa (RDEB); a new acne scar treatment using focal point technology is cleared in the US; and in our “Updates on Skin Cancer” feature, we hear about the advantages of 40-GEP testingWardrobe
Malfunctionhttps://practicaldermatology.com/topics/practice-management/wardrobe-malfunction/20913/Top dermatologists share tips on dressing for success.